Main Timeline Video Share
May the Holiday Warm Hearts: Idram and IDBank Support the Children of Heroes Beneficiaries of the "By Your Side" program at IDBank AraratBank Named Large CSR Company of the Year Idram Joins the Fight Against Food Insecurity Ucom’s Renovated Sales and Service Center in Yerevan Mall Reopens 1% idcoin instead of New Year’s suffering: practical tips Idram Junior Donated Books to Schools Big Christmas Market with Idram, IDBank and idplus Ucom Supports Wildlife Monitoring in Ararat Region IDBank, Idram, and idplus at the Big Christmas Market Converse Bank Deputy CEO and CFO, Grant Akopian, Elected to BACEE Board Ucom and SunChild NGO Install a Solar Plant in Alaverdi Kindergarten
What to do If you’ve already become a victim of fraudIdram and IDBank participated in Sevan Startup SummitArmenian National Festival Takes Place under AraratBank's SponsorshipArmDrone Community will launch a One-Month Free Educational Program with Ucom’s SupportAmeriabank Receives Euromoney Award for Excellence 2025 as the Best Bank in ArmeniaAraratBank's “The Will to Get Back on Your Feet Again” Film Series to Be Featured at Armenian National FestivalOnline Payments via ApplePay Now Available for vPOS Clients of AmeriabankUcom Subscribers Increasingly Use Internet While RoamingHorizon Camp: With AraratBank's Support - Towards Leadership and Financial LiteracyIdram at Tech Week 2025Idram and Alipay+ Facilitate Cross-Border QR Payments in Armenia, Connecting Local Merchants with Global Digital Wallet Users"Business Process Optimization with AI" – a Course for the Senior Management of AraratBank A Protected Ecosystem thanks to Advanced Technology: Ucom and FPWC Join Forces DIALOG Organization - Partner of the “Born in Artsakh” ProgramMoody's upgrades Converse Bank's ratingsAraratBank participated in the WEPs regional experience-sharing workshopIDBank issues the 3rd, 4th and 5th tranches of bonds of 2025AraratBank: Special Rate for SWIFT Transfers up to EUR 20,000 IDBank Opens a New Branch at Homplex MallUcom Launches 5G Network in Abovyan and Ejmiatsin
Life

Multiple sclerosis drug shows promising efficacy

The multiple sclerosis drug is showing promising efficacy in fighting relapses and reducing fatigue.

Back in March 2001, the US Food and Drug Administration approved a drug called ponosimod for use in adult patients with various types of multiple sclerosis. Only now there are research data that show that some drug reduces the number of relapses of the disease and can reduce fatigue - one of the characteristic symptoms of multiple sclerosis.

The respected scientific journal JAMA Neurology has found that ponesimod is more effective in fighting fatigue in multiple sclerosis than another commonly used drug called teriflunomide. It is superior to teriflunomide in reducing relapse rates and reducing the risk of new or existing lesions of myelin found on magnetic resonance imaging.

As reported by everydayhealth.com, ponesimod is used for various types of multiple sclerosis, including the most common relapsing remitting disease and active secondary progressive, which is the most severe. It is not accompanied by remissions and steadily leads to the disability of patients. It is people with this form of multiple sclerosis who show the appearance of new lesions of the myelin layer on MRI scans. Ponesimod must be taken once a day, treatment begins with a period of 14 days, then the doses are increased.